259 related articles for article (PubMed ID: 9245197)
1. [The need of prolonged BCG treatment in superficial bladder cancer is suggested by the development of a peripheral immune response induced by BCG].
Shekarsarai H; Zlotta AR; Drowart A; Van Vooren JP; De Cock M; Pirson M; Palfliet K; Jurion F; Vanonckelen A; Simon J; Schulman CC; Huygen K
Acta Urol Belg; 1997 Mar; 65(1):1-4. PubMed ID: 9245197
[TBL] [Abstract][Full Text] [Related]
2. [Immunotherapy in superficial bladder carcinoma].
Ríos González E; Martínez-Piñeiro Lorenzo L; Martínez-Piñeiro Caramés JA; de la Peña Barthel JJ
Arch Esp Urol; 2000 Dec; 53(10):879-92. PubMed ID: 11213392
[TBL] [Abstract][Full Text] [Related]
3. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
4. [Bacillus of Calmette-Guérin immunotherapy: which protocol?].
Saint F
Prog Urol; 2008 May; 18 Suppl 5():S99-104. PubMed ID: 18585635
[TBL] [Abstract][Full Text] [Related]
5. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
[TBL] [Abstract][Full Text] [Related]
6. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED
J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480
[TBL] [Abstract][Full Text] [Related]
7. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
8. Evolution of cellular and humoral response against Tuberculin and antigen 85 complex during intravesical treatment with BCG of superficial bladder cancer.
Zlotta A; Drowart A; van Vooren JP; Simon J; Schulman CC; Huygen K
Acta Urol Belg; 1994 Sep; 62(3):63-8. PubMed ID: 7976857
[TBL] [Abstract][Full Text] [Related]
9. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).
de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P;
J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181
[TBL] [Abstract][Full Text] [Related]
10. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
11. [Chemo-immunoprevention in superficial bladder cancer].
Adolphs HD; Bastian HP
Urologe A; 1986 Jan; 25(1):51-4. PubMed ID: 3962045
[TBL] [Abstract][Full Text] [Related]
12. [Response of lymphocytes and cytokines in patients with superficial bladder cancer treated with 1 mg of BCG vaccine instillations].
Rivera P; Inostroza J; Orio M
Actas Urol Esp; 1996 Oct; 20(9):812-7. PubMed ID: 9065092
[TBL] [Abstract][Full Text] [Related]
13. [Intravesical BCG therapy for superficial bladder cancer].
Segawa N; Iwamoto Y; Azuma H; Yamamoto K; Ueda H; Katsuoka Y
Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.
Decobert M; Larue H; Bergeron A; Harel F; Pfister C; Rousseau F; Lacombe L; Fradet Y
J Urol; 2006 Apr; 175(4):1506-11. PubMed ID: 16516037
[TBL] [Abstract][Full Text] [Related]
15. The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.
Reyes E; Carballido J; Manzano L; Moltó L; Olivier C; Alvarez-Mon M
Br J Cancer; 1999 Mar; 79(7-8):1162-7. PubMed ID: 10098752
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of patients with recurrent superficial bladder cancer with lyophilized Moureau-Rio de Janeiro BCG strain. Brazillian National Cancer Institute experience].
Quirino R; Ornellas AA; Wisnescky A
Prog Urol; 2005 Sep; 15(4):667-73. PubMed ID: 16459683
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K
Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
[TBL] [Abstract][Full Text] [Related]
18. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
19. [Results of a prospective study of chemoprophylaxis with alternating mitomycin-C and BCG: complete response and recurrence and progression index].
Nohales Taurines G; Cortadellas Angel R; Arango Toro O; Bielsa Gali O; Gelabert Mas A
Arch Esp Urol; 1996 Sep; 49(7):689-92. PubMed ID: 9020005
[TBL] [Abstract][Full Text] [Related]
20. Prostatic urothelial carcinoma: is transurethral prostatectomy necessary before bacillus Calmette-Guérin immunotherapy?
Gofrit ON; Pode D; Pizov G; Zorn KC; Katz R; Shapiro A
BJU Int; 2009 Apr; 103(7):905-8. PubMed ID: 19021623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
